The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.
暂无分享,去创建一个
C. Dinney | M. Rosenblum | P. Sweeney | A. Kamat | D. Davis | P. Thorpe | K. Mohamedali | D. Kedar | B. Eve | Samuel F Huang
[1] S. Ran,et al. The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. , 2005, Neoplasia.
[2] C. Dinney,et al. Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts , 2004, Cancer Research.
[3] J. Mavrommatis,et al. Non‐endothelial KDR/flk‐1 expression is associated with increased survival of patients with urothelial bladder carcinomas , 2003, Histopathology.
[4] A. Bikfalvi,et al. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. , 2002, Trends in pharmacological sciences.
[5] H. Serve,et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia , 2002, Leukemia.
[6] W. Wahli,et al. Differential Regulation of Vascular Endothelial Growth Factor Expression by Peroxisome Proliferator-activated Receptors in Bladder Cancer Cells* , 2002, The Journal of Biological Chemistry.
[7] Johannes Waltenberger,et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[8] R. Tiguert,et al. Prognostic markers in muscle invasive bladder cancer , 2002, World Journal of Urology.
[9] C. Dinney,et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] L. Ellis,et al. The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. , 2002, Seminars in cancer biology.
[11] D. Horsfall,et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. , 2002, Cancer research.
[12] N. Ferrara,et al. The Role of Vascular Endothelial Growth Factor in Angiogenesis , 2002, Acta Haematologica.
[13] H. Inoue,et al. Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth , 2002, International journal of cancer.
[14] Lei Xu,et al. Pancreas Microenvironment Promotes VEGF Expression and Tumor Growth: Novel Window Models for Pancreatic Tumor Angiogenesis and Microcirculation , 2001, Laboratory Investigation.
[15] L. Akslen,et al. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. , 2001, The American journal of pathology.
[16] Z. Estrov,et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] S. Jiang,et al. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[18] B. Wiedenmann,et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. , 2000, Gastroenterology.
[19] J. Li,et al. Intravesical immunotoxin as adjuvant therapy to prevent the recurrence of bladder cancer. , 2000, Chinese medical journal.
[20] D. McConkey,et al. Nitric Oxide–Dependent Activation of P53 Suppresses Bleomycin-Induced Apoptosis in the Lung , 2000, The Journal of experimental medicine.
[21] I. Clemmensen,et al. Angiogenic balance in human melanoma: Expression of VEGF, bFGF, IL‐8, PDGF and angiostatin in relation to vascular density of xenografts in vivo , 2000, International journal of cancer.
[22] A. Harris,et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. , 2000, Cancer research.
[23] A. Ullrich,et al. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications. , 2000, The oncologist.
[24] M. Kuwano,et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFα and IL‐1α , 2000 .
[25] J. Kurebayashi,et al. Expression of Vascular Endothelial Growth Factor (VEGF) Family Members in Breast Cancer , 1999, Japanese journal of cancer research : Gann.
[26] E. Brambilla,et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF‐R1‐Flt1 and VEGF‐R2‐Flk1/KDR) in non‐small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival , 1999, The Journal of pathology.
[27] H. Caffier,et al. Diagnostic value of serum VEGF in women with ovarian tumors. , 1999, Anticancer research.
[28] K. Syrigos,et al. Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer. , 1999, Hybridoma.
[29] S. Libutti,et al. Tumor angiogenesis and endothelial cell modulatory factors. , 1999, Journal of immunotherapy.
[30] J. Wu,et al. [Cloning and monoclonal antibody preparation of VEGF receptor KDR extracellular V-VII domain and KDR expression in carcinomas of different origins]. , 1999, Zhonghua zhong liu za zhi [Chinese journal of oncology].
[31] G. Neufeld,et al. Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[32] A. Frankel,et al. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma , 1998, American journal of hematology.
[33] J. Hoffmann,et al. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] Sabita Roy,et al. Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor‐toxin conjugate , 1997, International journal of cancer.
[35] A. Kaider,et al. Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease‐free survival , 1997, International journal of cancer.
[36] S. Fox,et al. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. , 1997, Journal of the National Cancer Institute.
[37] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[38] C. Osborne,et al. Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF). , 1996, The cancer journal from Scientific American.
[39] V. Bautch,et al. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. , 1996, Cancer research.
[40] S. K. Kim,et al. Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells , 1996, Cancer Immunology, Immunotherapy.
[41] M. Willingham,et al. IL2-ricin fusion toxin is selectively cytotoxic in vitro to IL2 receptor-bearing tumor cells. , 1995, Bioconjugate chemistry.
[42] C. Bucana,et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. , 1995, The Journal of urology.
[43] M. Barbareschi,et al. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. , 1995, The cancer journal from Scientific American.
[44] C. Bucana,et al. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[45] A. Harris,et al. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] M. Shibuya,et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.
[47] E. Manseau,et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. , 1993, The American journal of pathology.
[48] Brygida Berse,et al. Vascular permeability factor (VPF, VEGF) in tumor biology , 1993, Cancer and Metastasis Reviews.
[49] M. Rosenblum,et al. A gelonin-containing immunotoxin directed against human breast carcinoma. , 1992, Molecular biotherapy.
[50] H Ueno,et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.
[51] J. Murray,et al. A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin. , 1991, Molecular biotherapy.
[52] H. Koeppen,et al. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. , 1988, Cancer research.
[53] H. Juhl,et al. Selective killing of human bladder cancer cells by combined treatment with A and B chain ricin antibody conjugates. , 1987, Cancer research.
[54] F. Stirpe,et al. Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. , 1980, The Journal of biological chemistry.
[55] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[56] H. Kumamoto,et al. Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas. , 2002, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[57] A. Böhle,et al. Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer. , 2002, European urology.
[58] M. Kuwano,et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. , 2000, International journal of cancer.
[59] B. Fine,et al. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. , 2000, Gynecologic oncology.
[60] M. Korc,et al. Concomitant over‐expression of vascular endothelial growth factor and its receptors in pancreatic cancer , 2000, International journal of cancer.
[61] R. Masood,et al. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. , 1999, Cancer research.
[62] F. Aranda,et al. Microvessel quantitation in breast ductal invasive carcinoma. Correlation with proliferative activity, hormonal receptors and lymph node metastases. , 1996, Pathology, research and practice.
[63] M. Shibuya. Role of VEGF-flt receptor system in normal and tumor angiogenesis. , 1995, Advances in cancer research.
[64] N. Dubrawsky. Cancer statistics , 2022 .